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and Doreen A. Cantrell*
Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom
Phosphoinositide 3-kinase p110 delta (PI3K p110d) is pivotal for CD8+ T cell immune
responses. The current study explores PI3K p110d induction and repression of antigen
receptor and cytokine regulated programs to inform how PI3K p110d directs CD8+ T cell
fate. The studies force a revision of the concept that PI3K p110d controls metabolic
pathways in T cells and reveal major differences in PI3K p110d regulated transcriptional
programs between naïve and effector cytotoxic T cells (CTL). These differences include
differential control of the expression of cytolytic effector molecules and costimulatory
receptors. Key insights from the work include that PI3K p110d signalling pathways
repress expression of the critical inhibitory receptors CTLA4 and SLAMF6 in CTL.
Moreover, in both naïve and effector T cells the dominant role for PI3K p110d is to
restrain the production of the chemokines that orchestrate communication between
adaptive and innate immune cells. The study provides a comprehensive resource for
understanding how PI3K p110d uses multiple processes mediated by Protein Kinase B/
AKT, FOXO1 dependent and independent mechanisms and mitogen-activated protein
kinases (MAPK) to direct CD8+ T cell fate.
Keywords: PI3K, p110d, CD8+ T cells, TCR signalling, transcriptomics, cytokines, chemokinesINTRODUCTION
CD8+ cytotoxic T cells are critical cells for mammalian adaptive immune responses that clear
pathogen infected cells. The proliferation and differentiation of CD8+ T cells into cytolytic effector
cells (CTL) is directed by an integrated network of signals driven by the T cell antigen receptor
(TCR) and modulated by cytokines and cytokine receptors and costimulatory and inhibitory
receptors (1, 2). One rapid consequence of TCR engagement in CD8+ T cells is the production of
phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), the product of phosphoinositide 3-
kinase (PI3K). CD8+ T cells thus rapidly accumulate PtdIns(3,4,5)P3 following TCR engagement
(3–5) and sustain high levels of PtdIns(3,4,5)P3 as they differentiate to effector CTL (6, 7). Cellular
levels of PtdIns(3,4,5)P3 in T cells are controlled by a PI3K complex that contains the p110d catalyticorg June 2021 | Volume 12 | Article 6919971
Spinelli et al. PI3Kp110d Transcriptome in T Cellssubunit (PI3K p110d) (4, 8, 9). The importance of PI3K p110d is
emphasised by the discovery that both loss and gain of function
mutations of PI3K p110d cause primary immunodeficiency and
autoimmunity in humans and mice (10–13). Effective PI3K
p110d inhibitors, used clinically to treat immune dysfunction
and cancer, are available (14–17).
The importance of PI3K p110d for T cells makes it important
to understand the molecular details of how it controls T cell
function. In this context, PtdIns(3,4,5)P3 controls the activity of
the serine/threonine kinase PKB/AKT which phosphorylates the
transcription factor FOXO1 causing its exclusion from the
nucleus and terminating FOXO1 controlled transcription. In
naïve T cells, FOXO1 controls expression of transcription factors
and cytokine receptors that maintain T cell quiescence (18).
FOXO1 also controls expression of the adhesion molecules and
chemokine receptors that instruct T cell trafficking to secondary
lymphoid tissue (19–21). In pathogen activated and effector
CTL, PI3K p110d signalling keeps FOXO1 cytosolic and inactive
(22) to maintain CD8+ T cell effector function (23). The loss of
PKB/AKT activity causes nuclear relocation of FOXO1 resulting
in the induction of the transcriptional program required for
memory T cells (18, 23). FOXO1 is thus essential for memory
CD8+ T cell formation and maintenance (24–27) and may
control T cell exhaustion during chronic viral infections by to
controlling the expression of the inhibitory receptor PD-1 and
regulating T cell survival (28).
FOXO1 studies have given important insights about how
PI3K p110d controls CD8+ T cells but it is pertinent that PI3K
p110d signalling pathways go beyond the control of FOXO1.
There are thus multiple substrates for PKB/AKT and PI3K p110d
also modulates the activity of mitogen-activated protein (MAP)
kinases (29, 30). Furthermore, there has never been an unbiased
analysis or direct comparison of how PI3K p110d shapes
transcriptomes and proteomes in naïve versus effector CD8+ T
cells. In this respect, signal transduction outcomes can be shaped
by the epigenetic and metabolic remodelling that accompanies T
cell differentiation. Hence in naïve T cells the role of the TCR is
to initiate expression of biosynthetic and transcriptional
programs that drive T cell clonal expansion and differentiation.
In effector CD8+ T cells these programs are controlled by pro-
inflammatory cytokines and the role of the TCR is to trigger
execution of effector function (e.g. the production of cytokines
and degranulation of cytolytic effector molecules).
Accordingly, the current objective was to use RNA
sequencing, proteomic and secretome analysis to define the
contribution of PI3K p110d to antigen receptor regulated
programs in naïve and effector CD8+ T cells. For mechanistic
insights, we examined PI3K p110d controlled responses in wild
type (WT) and FOXO1 null effector CTL to understand how
much of PI3K signalling is directed by FOXO1. We also assessed
the importance of PKB/AKT and the MAP kinases as mediators
of PI3K p110d responses. This work provides a comprehensive
understanding of the targets for PI3K p110d signals in antigen
receptor activated naïve and effector CD8+ T cells and creates the
information framework necessary to predict the implications of
the therapeutic manipulation of PI3K p110d for CD8+ T cells.Frontiers in Immunology | www.frontiersin.org 2MATERIALS AND METHODS
Mice
For naïve and 24 h activated CD8+ T cells ± PI3K p110d
inhibitor, unstimulated and 4 h TCR activated CTL ± PI3K
p110d inhibitor transcriptomes, P14 transgenic mice (31) were
used (female mice, 9–13 weeks old).
FOXO1-GFPfl/fl mice were generated at Taconic. To allow
conditional deletion of FOXO1, exon 2, which includes the EGFP
sequence, was flanked by LoxP sites (32). Then to allow the
deletion of FOXO1-GFP in effector T cells, FOXO1-GFPfl/fl mice
were crossed to mice expressing the Cre recombinase under the
control of the granzyme B promoter sequence [Supplementary
Figure 5B and (33, 34)] generating FOXO1-GFPfl/fl GzmB
cre mice.
Female FOXO1-GFPfl/fl GzmB cre+ mice and control GzmB
cre+ mice aged between 11 and 27 weeks were used for RNA
sequencing of CTL cultured for 24 h in the presence or absence of
inhibitor. In some experiments FOXO1-GFPfl/fl GzmB cre−mice
were used as controls. Experimental mice were age and sex
matched. Mice were bred and maintained in the Biological
Resource Unit at the University of Dundee using procedures
that were approved by the University Ethical Review Committee
and under the authorisation of the UK Home Office Animals
(Scientific Procedures) Act 1986.
Cell Cultures
All cells were activated and cultured in complete RPMI 1640
media containing glutamine (Thermo Fisher Scientific/Gibco),
supplemented with 10% FBS (Gibco), penicillin/streptomycin
(Gibco) and 50 µM ß-mercaptoethanol (Sigma). All cells were
cultured at 37°C with 5% CO2.
–For ex vivo naïve CD8+ T cells, 24 h TCR activated and 24 h
TCR activated in the presence of the PI3K p110d inhibitor
IC87114 (10 µM synthesized in-house), three mice were used
per biological replicate. Cells from the three mice were pooled
and then equally divided into the three conditions. Three
biological replicates were generated per condition. Single cell
suspensions were generated by mashing lymph nodes in RPMI
media and filtered through a 70 µm cell strainer. For 24 h TCR
activated CD8+ T cells, they were suspended in complete RPMI
media with 100 ng/ml antigenic peptide [glycoprotein amino
acids 33–41 (gp33–41)], 20 ng/ml interleukin-2 (IL-2; Proleukin,
Novartis) and 2 ng/ml interleukin-12 (IL-12; PeproTech). Where
indicated, cells were treated with 10 µM IC87114 inhibitor.
DMSO was used as vehicle control. After 24 h, cells were
harvested by centrifugation and prepared for cell sorting to
isolate pure CD8+ T cell populations.
–To generate CTL from P14 transgenic mice, lymph nodes or
spleens from three mice were used to generate three biological
replicates. Lymph nodes were homogenised as described above.
Spleens were mashed in red blood cell lysis buffer (150 mM
NH4Cl, 10 mM KHCO3, 110 µM Na2EDTA pH 7.8), filtered
through a 70 µm cell strainer and then suspended in complete
RPMI media supplemented with 100 ng/ml gp33–41 peptide,
20 ng/ml IL-2 and 2 ng/ml IL-12 in 10 ml complete RPMI.June 2021 | Volume 12 | Article 691997
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further five days in complete RPMI media supplemented with 20
ng/ml IL-2. Cells were maintained at a cell density of 0.3 × 106
live cells/ml.
For transcriptomic and proteomic studies and western
blotting of TCR stimulated CTL: on day seven CTL were
plated at a cell density of 1 × 106 live cells/ml in complete
RPMI media supplemented with 20 ng/ml IL-2 and left to rest at
37°C with 5% CO2 for 1 h. CTL were then stimulated by adding
100 ng/ml gp33–41 peptide directly to the supplemented media
for 4 h in the presence or absence of IC87114 inhibitor (10 µM),
or MEK inhibitor PD184252 (2 µM, Division of Signal
Transduction Therapy (DSTT) Dundee). DMSO was used as
vehicle control. Cells were harvested, washed twice with HBSS
(Thermo Fisher Scientific/Gibco), snap frozen in liquid nitrogen
and stored at −80°C until further processing.
For secretomic studies of TCR stimulated CTL: on day seven
CTL were plated at a density of 1 × 106 live cells/ml in serum free
RPMI media (phenol red free, Thermo Fisher Scientific Gibco)
supplemented with 50 µM ß-mercaptoethanol (Sigma), Insulin-
Transferrin-Selenium 100× (ITS, Gibco) and 20 ng/ml IL-2 and
left to rest at 37°C with 5% CO2 for 1 h. CTL were then
stimulated as described above for 4 h in the presence or
absence of 10 µM IC87114 inhibitor or 2 µM PD184252
inhibitor or 1 µM AKT inhibitor 1/2 (Merck chemicals).
DMSO was used as vehicle control. Supernatants were then
collected, passed through a 0.22 mm filter, snap frozen in liquid
nitrogen and stored at −80°C until further processing.
For ELISA: CTL were plated at a density of 1 × 106 live cells/
ml in complete RPMI media supplemented with 20 ng/ml IL-2
and left to rest at 37°C with 5% CO2 for 1 h prior stimulation
with 100 ng/ml gp33–41 peptide added to the supplemented
media for 4 h in the presence or absence of 10 µM IC87114
inhibitor or 2 µM PD184252 inhibitor or 1 µM AKT inhibitor
1/2. DMSO was used as vehicle control. Supernatants were
collected, snap frozen in liquid nitrogen and stored at −80°C
until further processing.
–To generate CTL from FOXO1-GFPfl/fl GzmB cre+ mice
(FOXO1-GFP KO) and control GzmB cre+ mice (WT), lymph
nodes or spleens were used and single cell suspensions were
prepared as described above. Cells were activated with 0.5 µg/ml
anti-mouse CD3 (clone 145-2C11 Biolegend), 0.5 µg/ml anti-
mouse CD28 (clone 37.51 eBioscience), in 10 ml complete RPMI
media supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12. Cells
were activated for 48 h, then washed out and cultured for a
further five days in complete RPMI media supplemented with 20
ng/ml IL-2 and 2 ng/ml IL-12.
For transcriptomic studies, on day six cells were plated at a
density of 0.5 × 106 live cells/ml in complete RPMI media
supplemented with 20 ng/ml IL-2 and 2 ng/ml IL-12 and with
or without 10 µM IC87114 for 24 h. DMSO was used as vehicle
control. On day seven, media, containing all as above, was
refreshed 2 h before cells were harvested and prepared for
cell sorting.
–For FOXO1-GFP nuclear localisation: CTL from FOXO1-
GFPfl/fl GzmB cre− mice (expressing FOXO1-GFP taggedFrontiers in Immunology | www.frontiersin.org 3protein) were generated. Cells from WT mice (expressing
untagged FOXO1 protein) were used as negative control for
GFP expression. Spleens were used and single cell suspensions
were prepared as described above. Cells were activated with 0.5
µg/ml anti-mouse CD3, 0.5 µg/ml anti-mouse CD28, in 10 ml
complete RPMI media supplemented with 20 ng/ml IL-2 and 2
ng/ml IL-12. Cells were activated for 48 h, then washed out and
cultured in complete RPMI media supplemented with 20 ng/ml
IL-2. On days six or seven, cells were plated at a density of 1 × 106
live cells/ml in the presence or absence of IC87114 inhibitor for
1 h (10 µM). DMSO was used as vehicle control.
Cell Sorting
Cell sorting was performed on a Sony SH800S cell sorter (Sony
Biotechnology). Staining was performed in PBS supplemented
with 1% FBS. Sorting and cells collection for ex vivo naïve CD8+
T cells and 24 h TCR activated CD8+ T cell with or without
inhibitor was performed in RPMI 1640 containing glutamine,
supplemented with 1% FBS. Sorting and cell collection for
FOXO1-GFP KO and WT CTL was performed in RPMI 1640
containing glutamine, supplemented with 10% FBS.
Fluorophore-conjugated antibodies were obtained from BD
Biosciences, eBioscience or Biolegend.
–Ex vivo naïve CD8+ T cells were sorted as DAPI-
TCRß+CD8+CD62Lh iCD44lo . 1 µg Fc block (BD
Pharmingen) per million cells was used to block Fc
receptors. Cells were then stained with the fluorophore-
conjugated antibodies TCRß-PerCPCy5.5 (H57-587), CD4-
PECy7 (RM4-5), CD8-PE (53-6.7), CD44-APC (IM7),
CD62L-FITC (MEL-14) and DAPI in PBS 1% FBS.
–24 h TCR activated CD8+ T cells with or without inhibitor were
stained with the fluorophore-conjugated antibody CD8-APC
and DAPI and sorted as DAPI−CD8+.
–CTL FOXO1-GFP KO from FOXO1-GFPfl/fl GzmB cre+ mice
were stained with the fluorophore-conjugated antibody CD8-
APC and DAPI and sorted as DAPI−CD8+GFP−.
–CTL WT from GzmB cre+ mice were stained with the
fluorophore-conjugated antibody CD8-APC and DAPI and
sorted as DAPI−CD8+.
All sorted cells were then washed twice with HBSS before being
snap frozen in liquid nitrogen and stored at −80°C until
further processing.
Forward/Side Scatter
Forward and side scatter profiles for sorted WT CTL treated or
untreated for 24 h with the PI3K p110d inhibitor were acquired
on a FACSVerse using FACSuite software and data were
analysed using FlowJo software version 10.6.1 (Treestar).
Flow Cytometry Analysis of Nuclear
Extract for FOXO1-GFP Localisation
Harvested cells were washed in PBS supplemented with 1% FBS
and then either not lysed or lysed in 300 µl ice-cold nuclear
extraction buffer (3.8 mM trisodium citrate, 9.6 mMNaCl, 0.05%June 2021 | Volume 12 | Article 691997
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inhibition increases FOXO1 nuclear localisation but not the total
level of FOXO1 protein) and the nuclei of lysed cells were then
fixed immediately with 300 µl ice-cold IC fixation buffer
(eBioscience) for 15 min at 4°C. After washing, nuclei were
stained with DAPI. Samples were acquired on Novocyte (Acea
Biosciences Inc.) using Novo Express software. Data analysis was
performed using FlowJo software version 10.6.1 (Treestar).
ELISA
ELISA kits for GZMB, IFNg and TNFa (Invitrogen) were used
according to the manufacturer’s instructions to determine the
effects of 4 h TCR stimulation and PI3K p110d, MEK or AKT
inhibitor treatments on the secretion of these proteins.
Experiments were performed in biological triplicate. Statistical
analysis was performed with Prism 7 for Mac OS X using
unpaired, unequal variance t-test with Welch’s correction. The
P values are considered as follow: *P <0.05, **P <0.01, ***P
<0.001, ****P <0.0001, ‘ns’ not statistically significant.
Western Blotting
Cell pellets were lysed in RIPA buffer (100 mM HEPES, pH 7.4,
150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate,
10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM TCEP, and
protease and phosphatase inhibitors (Roche)). Cell lysates were
sonicated and then centrifuged at 4°C at 13,000 rpm for 10 min.
LDS sample buffer (1×) (Life Technologies) and tris(2-
carboxyethyl)phosphine (TCEP, 25mM) was added to the
samples prior to incubation at 100°C for 10 min. Samples were
loaded and separated by SDS-PAGE (NuPAGE precast gels, Life
Technologies), and then transferred to nitrocellulose membranes
(Whatman). Blots were probed with the following antibodies:
AKT p-S473 (Cell Signalling and Technology, #4058), AKT p-
T308 (Cell Signalling and Technology, #4056), AKT (Cell
Signalling Technology, #9272), SMC1 (Bethyl Laboratories,
A300-055A), p44/42 MAPK p-T202/Y204, Cell Signalling and
Technology, #9106) and p44/42 MAPK (Cell Signalling and
Technology, #9102). Horseradish peroxidase (HRP)-conjugated
secondary antibodies were used (Thermo Scientific).
Chemiluminescence was measured using an Odyssey Fc
Imaging System (Licor). Image Studio Software (LI-COR) was
used to quantify chemiluminescence detected using the Odyssey
system. Total protein bands were normalised to the
corresponding SMC1 loading control, and then phosphorylated
protein bands were normalised to the total protein band and
normalised to a control sample (+TCR 4 h). Statistical analysis
was performed with Prism 7 for Mac OS X using unpaired,
unequal variance t-test with Welch’s correction. The P values are
considered as follow: *P <0.05, **P <0.01, ***P <0.001, ****P
<0.0001, 'ns' not statistically significant.
RNA Extraction for
RNA-Sequencing (RNAseq)
Total RNA was extracted from frozen cell pellets of sorted naïve
CD8+ T cells and TCR activated with or without inhibitor, CTL
either not TCR stimulated or TCR stimulated for 4 h in theFrontiers in Immunology | www.frontiersin.org 4presence or absence of inhibitor, and WT or FOXO1-GFP KO
CTL with or without 24 h inhibitor treatment using Qiagen
RNAeasy mini kit (Qiagen) as per manufacturer’s instructions.
Total RNA was quantified using a Nanodrop ND-1000
spectrophotometer. Three biological replicates were generated
for each condition.
For naïve CD8+ T cells less than 1 µg of total RNA was
supplied; for TCR activated with or without inhibitor cells and all
CTL samples 1 µg of total RNA was supplied to the Finnish
Functional Genomics Centre of Turku Biosciences whom
prepared the libraries and performed the sequencing.
RNA Libraries Preparation and HiSeq
Sequencing Run Information
The quality of the total RNA samples was inspected using Agilent
Bioanalyzer 2100 or Advanced Analytical Fragment Analyzer
and the concentration of the samples was measured with
Nanodrop ND-2000 (Thermo Scientific) or Qubit Fluorometric
Quantitation (Life Technologies). Libraries preparation was
started from 300 ng of total RNA using the Illumina TruSeq
Stranded mRNA sample preparation kit (15031047) as per
manufacturer’s instructions. Data presented here were run as
three independent experiments as follows: one lane for naïve/
TCR 24 h activated cells with or without inhibitor (naïve/TCR
activated 24 h ± inhibitor) (this lane included also an
unpublished dataset not part of this manuscript); one lane for
CTL unstimulated or TCR 4 h stimulated with or without
inhibitors (Unstim/TCR stimulated 4 h CTL ± inhibitors); and
one lane for WT and FOXO1-GFP KO CTL with or without
inhibitor for 24 h (WT/FOXO1-GFP KO CTL ± inhibitor 24 h).
The quality of the libraries was confirmed with Advanced
Analytical Fragment Analyzer and the concentrations of the
libraries were quantified with Qubit Fluorometric Quantitation
(Life Technologies). Libraries were sequenced using Illumina
HiSeq 3000 (naïve/TCR activated ± inhibitor) or Illumina HiSeq
2500 (TCR stimulated CTL ± inhibitors) or Illumina HiSeq 3000
(WT/FOXO1-GFP KO CTL ± inhibitor) instruments using
paired-end sequencing chemistry and 75 bp (naïve/TCR
activated ± inhibitor) or 100 bp (TCR stimulated CTL ±
inhibitors) or 75 bp (WT/FOXO1-GFP KO CTL ± inhibitor)
read length. The typical yields are 120–150 × 106 paired-end
reads per lane on Illumina HiSeq 2500 and 260–310 × 106
paired-end reads per lane on Illumina HiSeq 3000.
RNAseq Data Processing
Naïve/TCR activated ± inhibitor and TCR stimulated CTL ±
inhibitors: raw reads were first aligned against theMus musculus
mm10 reference genome using the STAR aligner (34) (versions
2.5.2b or 2.4.2a) and then associated with known genes using the
RefSeq annotation. The number of reads associated with each
gene was counted using subreads package (versions 1.5.1 and
1.5.0). Genome (Mus Musculus mm10) and reference gene
annotations (RefSeq based annotation) were downloaded from
Illumina iGenomes web site.
WT/FOXO1-GFP KO CTL ± inhibitor: read quality was
evaluated and confirmed using MultiQC (35). Raw reads wereJune 2021 | Volume 12 | Article 691997
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reference genome using the STAR aligner (34) (version 2.7.1a),
with ‘outFilterType BySJout’ option to reduce the number of
spurious junctions. The STAR quantMode GeneCounts option
was used to map aligned reads to genes to generate a gene counts
matrix, using the annotation file GRCm38.98 (Ensembl).
For all experiments, the noise from low count genes was reduced
using the filterByExpr function. The resulting count matrix was
normalised by the Trimmed Mean of M-values (TMM) method
using the edgeR package (36, 37). EdgeR RPKM function was used
on TMM-normalised counts to calculate FPKM values, with total
exon length calculated using GenomicRanges (38) as the sum of the
non-overlapping exonic regions for a gene.
Differential expression analysis was performed using Limma
package (39). Reads were converted to log2 counts per million
and precision weighted using the voom function. A linear model
was fitted to each gene and empirical Bayes moderated t-statistics
were applied. P values were adjusted to control the global false-
discovery rate.
All scripts used to perform analysis are available from authors
upon request.
Statistics and Calculations RNAseq Data
Genes were defined as differentially expressed if they had an adj.
P value <0.05 and a fold change >2 or <0.5 (Naïve/TCR activated ±
inhibitor and TCR stimulated CTL +/- inhibitors); and a fold
change >1.5 or <0.67 (WT/FOXO1-GFP KO ± inhibitor). *adj.
P <0.05 and fold change >2 or <0.5 and fold change >1.5 or <0.67.
For the gene ontology (GO) Term enrichment analysis, GO
terms enriched in the statistically significant changed gene were
identified using the functional annotation tools within DAVID
Bioinformatics Resources 6.8, NIAID/NIH (http://david.ncifcrf.
gov). The top 5 GO terms describing “biological process”
annotation were identified based on P value and terms
represented by <3 genes in the changed gene list were excluded
from the analysis.
Heatmaps were generated using the Morpheus tool from the
Broad Institute (http://software.broadinstitute.org/morpheus).
Heatmap in Figure 2B was arranged with IFNg positioned at
the top and with all mRNA ranked according to similarity using
the nearest-neighbor analysis and Pearson correlation. Heatmap
in Figure 2D was arranged with Aacs positioned at the top. The
other heatmaps, with the exclusion of heatmaps in Figures 6F, G,
were arranged with the indicated mRNA on the top and the
others ranked according to similarity using the nearest-neighbor
analysis and Pearson correlation. Heatmaps in Figures 6F, G
were arranged following the order of Figures 3G, H.
Venn diagrams were generated using Venny 2.1 from
BioinfoGP (http://bioinfogp.cnb.csic.es/tools/venny) (40).
Proteomics Sample Preparation
Cell pellets were lysed in 0.5 ml urea lysis buffer (8 M urea, 100
mM Tris pH 8.0, protease (cOmplete Mini EDTA-free, Roche)
and phosphatase inhibitors (PhosSTOP, Roche) and vigorously
mixed for 30 min at room temperature. Samples were sonicated
with a Branson digital sonicator and protein concentration was
determined by BCA assay as per manufacturer’s instructionsFrontiers in Immunology | www.frontiersin.org 5(Thermo Fisher Scientific). Lysates were reduced with 10 mM
dithiothreitol (DTT) and incubated at 30°C for 30 min before
being alkylated with 50 mM iodoacetamide (IAA) in the dark at
room temperature for 45 min. Lysates were then diluted with tris
buffer (100 mM tris pH 8.0, 1 mM CaCl2) to 4 M urea. LysC
(Wako), reconstituted in tris buffer, was added to the samples at a
50:1 (protein:LysC) ratio and incubated at 30°C overnight.
Samples were then transferred to low-bind 15 ml Falcon tubes
(Eppendorf) and further diluted with tris buffer to 0.8 M urea
before trypsin (Promega), reconstituted with tris buffer, was
added at a ratio of 50:1 protein/trypsin and incubated at 30°C
for 8 h. After digestion, samples were adjusted to 1%
trifluoroacetic acid (TFA) prior desalting with C18 Sep-Pack
cartridges (Waters). The cartridges were washed twice with 1 ml
elution buffer (50% acetonitrile ACN/0.1%TFA) and equilibrated
twice with 1 ml wash buffer (0.1% TFA). Acidified peptides were
loaded twice and then washed three times with 1 ml washing
buffer. Peptides were eluted into Eppendorf Protein LoBind tubes
by 2 elutions of 600 ml elution buffer each and dried down in a
SpeedVac (Genevac).
Strong Anion Exchange Chromatography
Dried peptide samples were resuspended in 210 ml SAX sample
buffer (10 mM sodium borate–20% (v/v) acetonitrile), pH was
adjusted to pH 9.3 with 1 M NaOH if necessary, and then
fractionated with an UltiMate 3000 HPLC (high-performance
liquid chromatography) system equipped with an AS24 SAX
column. For the separation, the buffers used were 10 mM sodium
borate (pH 9.3) (SAX buffer A) and 10 mM sodium borate (pH 9.3),
500 mM NaCl (SAX buffer B). An exponential elution gradient
starting with Buffer A was used to separate the peptides into 16
fractions, which were collected and desalted with Sep-Pack C18 96-
well desalting plates (Waters). Desalted peptides were then dried
down with a SpeedVac (Genevac). Dried fractions were then
resuspended in 1% formic acid, and separated by nanoscale C18
reverse-phase chromatography (UltiMate 3000 RSLCnano System,
Thermo Fisher Scientific) before being electrosprayed into the linear
trap quadrupole–Orbitrap mass spectrometer (LTQ Orbitrap Velos
Pro; Thermo Fisher Scientific) as described previously (22). The
chromatography buffers used were as follows: HPLC buffer A (0.1%
formic acid), HPLC buffer B (80% acetonitrile and 0.08% formic
acid), and HPLC buffer C (0.1% formic acid). Peptides were then
loaded onto an Acclaim PepMap100 nanoViper C18 trap column
(100 mm inner diameter, 2 cm; Thermo Fisher Scientific) in HPLC
buffer C with a constant flow of 5 ml/min. After trap enrichment,
peptides were eluted onto an EASY-Spray PepMap RSLC
nanoViper, C18, 2 mm, 100 Å column (75 mm, 50 cm; Thermo
Fisher Scientific) using the following buffer gradient: 2% B (0 to
3 min), 2 to 40% B (3 to 128 min), 40 to 98% B (128 to 130 min),
98% B (130 to 150 min), 98 to 2% B (150 to 151 min), and
equilibrated in 2% B (151 to 180 min) at a flow rate of 0.3 ml/min.
The eluting peptide solution was automatically electrosprayed into
the coupled linear trap quadrupole–Orbitrap mass spectrometer
(LTQ Orbitrap Velos Pro; Thermo Fisher Scientific) using an
EASY-Spray nanoelectrospray ion source at 50°C and a source
voltage of 1.9 kV (Thermo Fisher Scientific). The mass spectrometer
was operated in positive ion mode. Full-scan MS survey spectraJune 2021 | Volume 12 | Article 691997
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the Orbitrap with a resolution of 60,000. Data were collected using
data-dependent acquisition (DDA): the 15 most intense peptide
ions from the preview scan in the Orbitrap were fragmented by
collision-induced dissociation (normalized collision energy, 35%;
activation Q, 0.250; activation time, 10 ms) in the LTQ after the
accumulation of 5,000 ions. Precursor ion charge state screening
was enabled, and all unassigned charge states as well as singly
charged species were rejected. The lock mass option was enabled for
survey scans to improve mass accuracy. MS was performed by the
Proteomics Facility, University of Dundee, UK.
Processing and Analysis
of Proteomic Data
The data were processed, searched and quantified with the
MaxQuant software package (version 1.6.10.43). Proteins and
peptides were identified using a hybrid database from databases
in Uniprot release 2020 06 as described in Marchingo et al. (41).
The following search parameters were used: protein N-terminal
acetylation, methionine oxidation, glutamine to pyroglutamate,
and glutamine and asparagine deamidation were selected as
variable modifications; carbamidomethylation of cysteine
residues was set as a fixed modification; Trypsin and LysC
were selected as the proteolytic enzymes; up to two missed
cleavages were permitted; protein and PSM False discovery
rates was set to 0.01 and matching of peptides between runs
was switched off. Perseus software package (version 1.6.6.0) was
used for data filtering and protein copy number quantification.
Proteins were quantified from unique (found only in a specific
protein group) and razor (peptides assigned to a specific protein
group without being unique to that group) peptides. The data set
was filtered to remove proteins categorised as “contaminants”,
“reverse” and “only identified by site”. Copy numbers were
calculated using the proteomic ruler plugin as described in
Wisniewski et al. (42). Copy numbers of histones in a diploid
mouse cell get assigned to the summed peptide intensities of all
histones present in a sample. The ratio between the histone
peptide intensity and the summed peptide intensities of the other
identified proteins is then used to estimate copy number per cell
for all identified proteins in the data set.
Statistics and Calculations
Proteomic Data
Three biological replicates were generated. P values were
calculated via a two-tailed, unequal-variance t-test on log10
transformed copy number per cell values in Microsoft Excel.
P values <0.05 were considered as being statistically significant.
Fold change >2 or <0.5 were considered as cut-off. Heatmaps
were generated using the Morpheus tool from the Broad Institute
(http://software.broadinstitute.org/morpheus). *P <0.05 and fold
change >2 or <0.5.
Secretomics Sample Preparation
For this experiment, 400 ml of supernatant was used for each sample
and peptides were generated using the S-Trap mini column method
(Protifi). Briefly, samples were mixed on a shaker at 1,000 rpm at
room temperature for 5 min after addition of 10 mM TCEP and 50Frontiers in Immunology | www.frontiersin.org 6mMTEAB (Triethylammonium bicarbonate) and then transferred to
a ThermoMixer shaking at 500 rpm at 95°C for 5 min before being
mixed again at 1,000 rpm at room temperature for 5 min. Samples
were alkylated with 20mM Iodoacetamide (IAA) in the dark at room
temperature for 1 h and protein concentration was determined using
the EZQ method (Thermo Fisher Scientific) according to the
manufacturer’s instructions. Lysates were acidified by addition of
1.2% phosphoric acid and then mixed by vortexing. S-Trap binding
buffer (90%methanol and 100mMTEAB pH 7.1) was added at a 1:7
ratio of lysate to S-Trap binding buffer, loaded on S-Trap mini
columns (Protifi) and then centrifuged at 6,500 rpm for 30 s. Bound
protein was washed five times by addition of 400 ml of S-Trap binding
buffer and centrifugation at 6,500 rpm for 30 s. Digestion buffer (125
ml) containing trypsin in a ratio protein 1:trypsin 20 was added into
the top of the column and incubated at 47°C for 2 h without shaking.
Peptides were then eluted by addition and centrifugation of 80 ml of
digestion buffer, 80 ml of 0.2% aqueous formic acid and 80 ml of 50%
aqueous acetonitrile containing 0.2% formic acid. Eluted peptides
were dried down in a SpeedVac (Genevac) and then reconstituted in
5% formic acid by shaking at 1,000 rpm at 30°C for 1 h. Peptides were
run on a Q Exactive Plus Hybrid Quadrupole-Orbitrap mass
spectrometer (Thermo Fisher Scientific) as single shot in a data-
dependent acquisition (DDA) mode (120 min). MS was performed
by the Proteomics Facility, University of Dundee, UK. The data were
processed, searched and quantified as described above with only
trypsin selected as proteolytic enzyme. Raw intensity for each replicate
was normalised to the corresponding control and expressed as %
intensity relative to TCR. Statistical analysis was performed with
Prism 7 for Mac OS X using unpaired, unequal variance t-test with
Welch’s correction. The P values are considered as follow: *P <0.05,
**P <0.01, ***P <0.001, ****P <0.0001.RESULTS
PI3K p110d Control of Antigen
Receptor Transcriptional Programs
in Naïve CD8+ T Cells
TCR driven activation of naïve T cells is the key step in directing
the differentiation of effector T cells. Therefore, to understand
how PI3K p110d controls CD8+ T cell differentiation we first
assessed the contribution of PI3K p110d signalling pathways to
the transcriptional remodelling initiated by the TCR. The cell
model used was P14 CD8+ T cells expressing a TCR specific for
lymphocytic choriomeningitis virus (LCMV) glycoprotein peptide
gp33–41. To define the PI3K p110d transcriptional programs we used
RNA sequencing to examine the transcriptome of naïve CD8+ T cells
before and after 24 h of activation with the LCMV glycoprotein
peptide gp33–41 in the presence or absence of the selective PI3K
p110d inhibitor IC87114 (PI3Kdi). In these experiments we
quantified 11,262 mRNA and using a fold change cut off >2 fold
and adj. P value <0.05 we saw that the abundance of 5,613 mRNA
was modified by antigen receptor engagement (Figure 1A;
Supplementary Table 1 and Supplementary Datasheet 1). There
are a number of mRNA (2,722), which represent around 24% of the
total transcriptome measured, that are expressed in naïve T cells andJune 2021 | Volume 12 | Article 691997
Spinelli et al. PI3Kp110d Transcriptome in T Cellsdownregulated upon immune activation including mRNA encoding
transcription factors whichmaintain pluripotency and cell quiescence
(e.g.Klf2 and Tcf7), translational repressors such as Pdcd4 and growth
factor receptors such as the Il7 and Il6 receptors (Supplementary
Table 1). There are also a large number of mRNA (2,891), around
26% of the total transcriptomemeasured, whose abundance increases
following immune activation and this includes mRNA encoding
proteins annotated in a GO term enrichment analysis as cell cycle
machinery and ribosomal biogenesis (Figure 1B and Supplementary
Table 1) but also includes nutrient transporters (Figure 1C),
transcription factors (Figure 1D) and a wide array of cytokines,
growth factors and chemokines (Figure 1E).
What are the consequences of inhibiting PI3K p110d during
TCR activation on the CD8+ T cell transcriptome? Overall, PI3K
p110d inhibition controlled the expression of 670 mRNA (>2 fold
change threshold and an adj. P value of <0.05) in the TCRFrontiers in Immunology | www.frontiersin.org 7activated CD8+ T cells (Figure 2A), which represent 6% of the
total 11,262 mRNA identified. There are 257 mRNA whose
expression is repressed and more than 400 mRNA whose
expression is increased by loss of PI3K p110d activity
(Supplementary Table 2 and Supplementary Datasheet 1).
The selectivity of the effects of PI3K p110d inhibition is striking
as shown by Figure 2B which uses nearest neighbor analysis and
Pearson correlation to group and align the expression profile of
11,262 mRNA in naïve, TCR activated CD8+ T cells and CD8+ T
cells activated via their TCR in the presence of the PI3K p110d
inhibitor. These data show that a large portion of the TCR
regulated transcriptional programs is PI3K p110d independent.
Of note, PI3K p110d does not mediate TCR induced changes in
the abundance of transcripts encoding the metabolic machinery
that mediate glycolysis, one carbon or fatty acid metabolism




FIGURE 1 | Remodelling of CD8+ T cell transcriptome in response to immune activation. RNA sequencing was used to characterise the transcriptome of sorted
ex vivo naïve or 24 h gp33–41 peptide activated (TCR) P14 CD8+ T cells. (A) Volcano plot of mRNA expression of 24 h TCR activated versus naïve CD8+ T cells.
mRNA significantly different between the two populations (fold change >2 or <0.5; adj. P values <0.05) shown in red. The horizontal dashed lines indicate an adj.
P value of 0.05 shown as −log10 while vertical dashed lines indicate a fold change of 2 and 0.5 shown as log2. The vertical solid line indicates the mean of log2 ratio.
(B) Enrichment analysis for biological processes for mRNA whose expression was induced upon TCR activation. The top 5 processes are presented. (C) Expression
profile (FPKM) of amino acid, lactate and glucose transporters. FPKM shown as the mean of three biological replicates ± standard deviation. * adj. P <0.05 and fold
change >2 or <0.5. (D) Volcano plot highlighting changes in transcription factor expression in response to 24 h TCR activation (GO:0003700 DNA binding
transcription factor activity). Annotated mRNA significantly different between the two populations compared are shown in red (fold change >2 or <0.5; adj. P value
<0.05). Transcription factors that showed no significant differences are shown in yellow. (E) Volcano plot highlighting mRNA expression of cytokines, growth factors
and chemokines whose expression was induced in response to 24 h TCR activation (GO:0005125 Cytokine activity and GO:0008009 Chemokine activity).
Annotated cytokines and growth factors (green) and annotated chemokines (pink) that were significantly upregulated upon TCR stimulation (fold change >2 or <0.5;
adj. P value <0.05). Input data for highlighted mRNA in (D, E) are listed in Supplementary Datasheet 1.June 2021 | Volume 12 | Article 691997
Spinelli et al. PI3Kp110d Transcriptome in T CellsTCR engagement switches on expression of the transcription
factors Myc and Hif1 alpha (Hif1a), which control expression of
amino acid transporters and glucose transporters (41, 43, 44)
respectively, even in the absence of PI3K p110d activity
(Figure 2E). Indeed expression of Hif1a mRNA was increased
relative to controls in cells activated in the absence of PI3K p110d
activity. The selectivity of the effects of PI3K p110d signalling isFrontiers in Immunology | www.frontiersin.org 8also highlighted by exploring the impact on the expression of
mRNA encoding key transcription factors that control CD8+ T
cell differentiation: over 300 transcription factors were identified
using the annotation DNA binding/transcription factor activity
(GO:0003700) and only 31 are controlled by PI3K p110d
(Figure 2F and Supplementary Datasheet 1). As examples, the
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FIGURE 2 | PI3K p110d control of antigen receptor transcriptional programs in naïve CD8+ T cells. P14 CD8+ T cells were activated in vitro with the gp33–41
peptide in the presence or absence of the PI3K p110d inhibitor IC87114 (PI3Kdi) for 24 h. (A) Impact of PI3K p110d inhibition on mRNA expression. Volcano plot
shows the ratio of PI3K p110d treated versus untreated TCR activated CD8+ T cells. mRNA significantly different between the two populations (fold change >2
or <0.5; adj. P values <0.05) shown in red. The horizontal dashed lines indicate an adj. P value of 0.05 shown as −log10 while vertical dashed lines indicate a fold
change of 2 and 0.5 shown as log2. The vertical solid line indicates the mean of log2 ratio. (B) Heatmap of CD8
+ T cells naïve, TCR activated 24 h ± PI3K p110d
inhibitor (PI3Kdi) transcriptomes. Heatmap was arranged with Ifng positioned at the top and shows the relative mRNA abundance graded from low (blue) to high (red)
per row. Input data for the heatmap are listed in Supplementary Datasheet 1. (C) Summed mRNA expression (FPKM) of genes annotated as glycolytic process
(GO:0006096), and one-carbon metabolic process (GO:0006730). FPKM represented as the mean of three biological replicates ± standard deviation. Input data
are listed in Supplementary Datasheet 1. (D) Heatmap of mRNA encoding enzymes that mediate fatty acid metabolism (Fatty acid metabolic process
GO:0006631). The heatmap shows the relative mRNA abundance graded from low (blue) to high (red) per row. Input data for the heatmap are listed in
Supplementary Datasheet 1. (E, H, J) mRNA expression levels (FPKM) of Myc, Hif1a, Tnfrsf9/4-1BB, Cd28, Icos, Gzmb and Prf1. FPKM shown as the mean of
three biological replicates ± standard deviation. * adj. P <0.05 and fold change >2 or <0.5. (F) Heatmap of more than 300 mRNA annotated as DNA binding/
transcription factor activity or added manually (GO:0003700). Heatmap was arranged with Tbx21 mRNA positioned at the top and shows the relative mRNA
abundance graded from low (blue) to high (red) per row. Input data for the heatmap are listed in Supplementary Datasheet 1. (G) Enrichment analysis for
biological processes for mRNA whose expression was reduced in TCR activated CD8+ T cells by PI3K p110d inhibition. The top 5 processes are presented.
(I) Volcano plot highlighting the effect of PI3K p110d inhibition on mRNA expression of cytokines, growth factors and chemokines induced in response to 24 h TCR
activation (GO:0005125 Cytokine activity and GO:0008009 Chemokine activity). Shown in green are annotated cytokines and growth factors and shown in pink are
annotated chemokines that were significantly regulated in response to PI3K p110d inhibition (fold change >2 or <0.5; adj. P value <0.05). Cytokines, growth factors
and chemokines that showed no significant differences are shown in yellow. Input data are listed in Supplementary Datasheet 1.
Spinelli et al. PI3Kp110d Transcriptome in T Cellsnot PI3K p110d dependent. Nor does PI3K p110d inhibition
prevent TCR induction of Tbx21, Blimp1 and Irf4: key drivers of
CD8+ T cell differentiation (Figure 2F and Supplementary
Figure 2A). Nevertheless, there are some key CD8+ T cell
transcription factors whose expression is PI3K p110d dependent
including Eomes (Figure 2F and Supplementary Figure 2A).
There are also increases in expression of mRNA encoding the
transcriptional repressors BACH2 and ID2 in PI3K p110d
inhibitor treated cells (Figure 2F and Supplementary Figure 2A).
What are the PI3K p110d controlled processes in T cells?
Here GO term enrichment analysis reveals the dominant effect of
PI3-kinase signalling pathways in TCR activated cells is to
control expression of transcripts annotated as ‘immune
response molecules’ (Figure 2G). For example, TCR triggering
induces an increase in expression of mRNA encoding the
important T cell costimulatory molecules 4-1BB, CD28 and
ICOS: TCR mediated upregulation of mRNA encoding 4-1BB
is dependent on PI3K p110d; whereas Icos and Cd28 mRNA is
increased in PI3K p110d inhibitor treated cells (Figure 2H).
Antigen activation also causes T cell to switch on expression
of mRNA encoding a diverse array of cytokines, chemokines and
cytotoxic effector molecules. These include Interleukin-2 (IL-2),
Interferon gamma (IFNg), Tumour necrosis factor (TNF),
Interleukin-3 (IL-3), Interleukin-24 (IL-24), Lymphotoxin-
alpha (LTa), Leukemia inhibitory factor (LIF), CD40 ligand
(CD40lg), Chemokine (C-C motif) ligand 3 (CCL3),
Chemokine (C-C motif) ligand 4 (CCL4), Chemokine (C
motif) ligand 1 (XCL1). The induction of this subset of mRNA
is all dependent on activation of PI3K p110d (Figure 2I). The
expression of mRNA encoding effector CD8+ T cell cytolytic
molecules like granzymes and perforin also depends on PI3K
p110d activity in TCR activated CD8+ T cells (Figure 2J).
PI3K p110d activation thus both positively and negatively
controls the expression of T cell costimulatory molecules and is
required for the production of multiple cytokines and effector
molecules that allow CD8+ T cells to mediate adaptive immune
responses. It is particularly striking that PI3K p110d activity is
required for the production of CCL3, CCL4 and XCL1 as theseFrontiers in Immunology | www.frontiersin.org 9are the essential chemokines used by immune activated CD8+ T
cells to direct their interactions with dendritic cells/monocytes
and macrophages (45, 46).
PI3K p110d Control of Transcriptional
Programs in Effector Cytotoxic
CD8+ T Cells
The TCR-PI3K p110d signalosome is remodelled during T cell
differentiation (47) but the contribution of PI3K p110d to TCR
triggered transcriptional programs in effector CD8+ T cells has
not been assessed. To address this question, antigen-primed P14
TCR transgenic CD8+ T cells were clonally expanded in IL-2 to
produce differentiated CTL. RNA sequencing then compared the
transcriptome of CTL before and after retriggering of the TCR
with the LCMV glycoprotein peptide gp33–41 in the presence or
absence of the PI3K p110d inhibitor IC87114. The data show that
out of 11,022 mRNA, TCR triggering induces increased
expression of 1,039 mRNA and downregulated expression of
1,294 mRNA (fold change cut off >2 and an adj. P value <0.05),
representing just over 20% of the total transcriptome measured
(Figure 3A; Supplementary Table 3 and Supplementary
Datasheet 2). The upregulated mRNA in TCR activated CTL
encode cytokines, growth factors and chemokines highlighting
how one key role of antigen receptor triggering in effector T cells
is to produce molecules that communicate pathogen recognition
to other cells of the immune system (Figures 3B, C). The
downregulated mRNA in TCR activated CTL encode genes
annotated in a GO term enrichment analysis as “cell cycle”
(Figure 3D) that includes E2F transcription factors (E2f1-E2f2-
E2f7-E2f8), cyclin A2 (Ccna2), cyclin B2 (Ccnb2) and cyclin D3
(Ccnd3) (Supplementary Figures 3A, B).
As in the naïve T cells, only a small fraction (less than 3%) of
the TCR induced transcriptional programs is sensitive to
inhibition of PI3K p110d in CTL. Blocking PI3K p110d activity
decreased expression of approximately 185 mRNA and increased
the abundance of 78 mRNA (Figure 3E, Supplementary Table 4
and Supplementary Datasheet 2). Enrichment analysis of the
downregulated mRNA revealed that the top 3 enriched GOJune 2021 | Volume 12 | Article 691997
Spinelli et al. PI3Kp110d Transcriptome in T Cellsterms for PI3K p110d sensitive processes are biological processes
involving cytokines and chemokines (Figures 3F–H). Figure 3G
thus shows that PI3K p110d activity is required for the
production of mRNA encoding multiple cytokines including
Granulocyte–macrophage colony-stimulating factor (GM-CSF/
CSF2), IL-2, TNF, IL-3, IL-24, IL-10, Lta, CD40lg. Notably, PI3K
p110d activity is also required for the TCR induced production of
chemokine mRNA including CCL9 and XCL1 (Figure 3H).Frontiers in Immunology | www.frontiersin.org 10Moreover, the effects of PI3K p110d inhibition on expression
of mRNA encoding chemokines and cytokines were paralleled by
changes in the production of cytokine and chemokine proteins as
measured by high resolution mass spectrometry analysis of the
proteomes and secretomes of unstimulated or P14 CTL activated
with cognate peptide for 4 h in the presence or absence of the
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FIGURE 3 | PI3K p110d control of antigen receptor transcriptional programs in effector cytotoxic CD8+ T cells. P14 CTL were either left unstimulated or TCR
retriggered with the LCMV peptide in the presence or absence of the PI3K p110d inhibitor IC87114 (PI3Kdi) for 4 h and the transcriptome analysed by RNAseq.
(A) Impact of TCR retriggering on mRNA expression in CTL. Volcano plot showing the ratio for 4 h TCR retriggered versus unstimulated CTL. mRNA significantly
different between the two populations (fold change >2 or <0.5; adj. P values <0.05) shown in red. The horizontal dashed lines indicate an adj. P value of 0.05 shown as
−log10 while vertical dashed lines indicate a fold change of 2 and 0.5 shown as log2. The vertical solid line indicates the mean of log2 ratio. (B, D) GO term enrichment
analysis for biological processes for mRNA whose expression was up or downregulated by TCR retriggering. The top 5 processes are presented. (C) Volcano plot of
cytokines, growth factors and chemokines mRNA whose expression was induced in CTL by 4 h TCR retriggering (GO:0005125 Cytokine activity and GO:0008009
Chemokine activity). Annotated cytokines and growth factors (green) and annotated chemokines (pink) that were significantly upregulated upon TCR retriggering (fold
change >2 or <0.5; adj. P value <0.05). Input data are listed in Supplementary Datasheet 2. (E) Volcano plot showing the ratio of TCR stimulated CTL ± PI3K p110d
inhibitor (PI3Kdi). In red mRNA significantly different between the two populations (fold change >2 or <0.5; adj. P values <0.05). The horizontal dashed lines indicate an
adj. P value of 0.05 shown as −log10 while vertical dashed lines indicate a fold change of 2 and 0.5 shown as log2. The vertical solid line indicates the mean of log2
ratio. (F) Enriched GO terms for mRNA whose expression was reduced in TCR retriggered CTL in the absence of PI3K p110d activity. The top 5 biological processes
are presented. (G, H) Heatmaps of mRNA encoding (G) cytokines, growth factors and (H) chemokines annotated as Cytokine activity (GO:0005125) and Chemokine
activity (GO:0008009). The heatmaps show the relative mRNA abundance graded from low (blue) to high (red) per row. Input data for heatmaps are listed in
Supplementary Datasheet 2. (I) The proteome of P14 CTL either left unstimulated or TCR retriggered for 4 h in the presence or absence of the PI3K p110d inhibitor
IC87114 (PI3Kdi) was analysed by mass spectrometry. Volcano plot shows fold change in protein copy number between TCR retriggered CTL lacking PI3K p110d
activity and TCR retriggered CTL, highlighting the effect of PI3K p110d inhibition on the expression of TCR induced cytokine, growth factor and chemokine proteins. In
green annotated cytokines and growth factors and in pink annotated chemokines that were significantly regulated in response to PI3K p110d inhibition (fold change >2
or <0.5; P value <0.05). In yellow cytokines, growth factors and chemokines that showed no significant changes. Input data are listed in Supplementary Datasheet 4.
(J) mRNA expression levels (FPKM) of Gzmb and Prf1. FPKM shown as the mean of three biological replicates ± standard deviation. *adj. P <0.05 and fold change >2
or <0.5. (K) Mean protein copy number per cell of granzyme B (GZMB) calculated using the proteomic ruler method as described in Materials and Methods. *P <0.05
and fold change >2 or <0.5. (L) Granzyme B levels in supernatants of P14 CTL unstimulated and TCR retriggered in the presence or absence of PI3K p110d inhibitor
(PI3Kdi) determined by ELISA. Data shown as the mean of four biological replicates ± standard deviation and statistical analysis calculated by unpaired, unequal
variance t-test with Welch’s correction. The P values are considered asfollow: ****P < 0.0001 and ‘ns’ not statistically significant.
Spinelli et al. PI3Kp110d Transcriptome in T CellsIn TCR activated naïve T cells, PI3K p110d activity directed
expression of the cytolytic effector molecules granzyme B and
perforin (Figure 2J). mRNA and protein levels for these effector
molecules are already high in CTL (Figure 3J) [Supplementary
Figure 4A and (48)] However, neither granzyme nor perforin
expression is PI3K p110d regulated in CTL (Figure 3J). Here, an
important consideration is that a primary function of TCR
engagement in CTL is to induce degranulation of cytolytic effector
molecules. TCR activated CTL thus lose intracellular granzyme B
protein following TCR engagement (Figure 3K). This response is
not prevented by PI3K p110d inhibition, with the same amount of
granzyme B content remaining in the cell in CTL after 4 h
retriggering with or without inhibitor (Figure 3K). Analysis of
granzyme B levels in cell supernatants also failed to see an impact
of PI3K p110d inhibition on granzyme B exocytosis (Figure 3L).
PI3K p110d thus does not control the TCR mediated production of
cytolytic T cell granules or degranulation processes in CTL.
The Impact of Sustained Loss
of PI3K p110d Activity on CTL
Transcriptional Programs
In these initial CTL experiments we examined the impact of
PI3K p110d inhibition on an immediate (4 h) response of CTL to
TCR engagement. The rationale for this time choice was that
CTL activated via the TCR undergo activation induced cell death
making it difficult to interpret data from longer time points.
However, to explore further how PI3K p110d controls CTL
biology, we also examined the impact of sustained inhibition of
PI3K p110d on CTL phenotypes. In this context, CTL
maintained in IL-2 have high levels of PtdIns(3,4,5)P3
produced by sustained activity of PI3K p110d (6, 7). RNA
sequencing was thus used to compare the transcriptome of
CTL maintained for 24 h in the presence or absence of the
PI3K p110d inhibitor IC87114. In this setting, blocking PI3K
p110d activity did not affect the growth and death of effectorFrontiers in Immunology | www.frontiersin.org 11CD8+ T cells [Figures 4A, B and (23)] but did modulate the CTL
transcriptome. Figure 4C shows increased expression of 254
mRNA and decreased expression of 96 mRNA in CTL lacking
PI3K p110d act iv ity (Supplementary Table 5 and
Supplementary Datasheet 3). The mRNA dependent on
sustained PI3K p110d activity in CTL includes chemokines and
cytokines (Figure 4D). Interestingly, there is no PI3K
p110d regulation of mRNA encoding the costimulatory
molecules 4-1BB and ICOS (Figure 4E) or mRNA encoding
cytolytic effector molecules granzyme and perforin (Figure 4F).
The absence of any effect of PI3K p110d inhibition on
expression of cytolytic effector molecules and 4-1BB and ICOS
is a fundamental difference between naïve T cells and CTL
(Figures 2H, J and Figures 4E, F). One other difference, in
terms of the impact of PI3K p110d inhibition on TCR responses
in naïve T cells versus CTL, is the magnitude of the effects. There
are many more TCR regulated transcripts dependent on PI3K
p110d activity in naïve T cells than in CTL (Figure 4G).
What are the PI3K p110d regulated mRNA in CTL? The GO
term annotation for mRNA that increased in expression
following loss of PI3K p110d activity in CTL identified
molecules linked to the control of cell adhesion and migration,
notably CD62L (Sell) an adhesion molecule that controls T cell
trafficking into secondary lymphoid tissue and Ccr7 and
sphingosine 1-phosphate receptor 1 (S1pr1), chemokine
receptors that regulates lymphocyte entry and egress from
lymphoid tissues (Figures 4H, I, and Supplementary Table 5).
These have previously been described as proteins whose
expression is controlled by PI3K p110d (29, 49). mRNA that
increases in expression in CTL treated with the PI3K p110d inhibitor
also include the interleukin 7 receptor (Il7r) and the transcription
factors Tcf7 and Klf2 (Figure 4I and Supplementary Table 5).
Are there any new insights about the role of PI3K p110d in
effector CD8+ T cells from these experiments? One fundamental
observation is that sustained loss of PI3K p110d activity in CTLJune 2021 | Volume 12 | Article 691997






FIGURE 4 | Impact of sustained PI3K p110d inhibition on CTL transcriptional programs. WT CTL were maintained for 24 h in the presence or absence of the PI3K
p110d inhibitor IC87114 (PI3Kdi) and RNAseq was used to characterise their transcriptome. (A) Forward/side scatter flow cytometry analysis of IL-2/IL-12
maintained or 24 h inhibitor treated WT CTL. (B) Percentage of cell death at the end of the culture quantified by flow cytometry as proportion of cells DAPI positive.
(C) Volcano plot showing the ratio for 24 h PI3K p110d inhibitor (PI3Kdi) treated cells versus untreated WT CTL. mRNA significantly different between the two
populations shown in red (fold change >1.5 or <0.67; adj. P values <0.05). The horizontal dashed lines indicate an adj. P value of 0.05 shown as −log10 while vertical
dashed lines indicate a fold change of 1.5 and 0.67 shown as log2. The vertical solid line indicates the mean of log2 ratio. (D–F) Histograms showing mRNA
expression levels (FPKM) for Ifng, Ccl3, Ccl4, Tnfrsf9/4-1BB, Icos, Gzmb and Prf1. FPKM shown as the mean of three biological replicates ± standard deviation.
(G) Percentage of the impact of PI3K p110d inhibition on the total transcriptome of TCR activated naïve (left) and effector CD8+ T cells (right). (H) GO term
enrichment analysis for biological processes for mRNA whose expression was induced by sustained inhibition of PI3K p110d activity. The top 5 processes are
presented. (I) Heatmap of known FOXO1 targets in WT CTL cultured for 24 h in the presence or absence of PI3K p110d inhibitor (PI3Kdi): Sell, Il7r, S1pr1, Tcf7,
Ccr7 and Klf2. The relative mRNA abundance is graded from low (blue) to high (red) per row. Input data for the heatmap are listed in Supplementary Datasheet 3.
(J, K) mRNA expression levels (FPKM) of Ctla4 in (J) WT CTL ± PI3K p110d inhibitor (PI3Kdi) for 24 h and (K) in TCR stimulated CTL ± PI3K p110d inhibitor (PI3Kdi)
for 4 h. FPKM shown as the mean of three biological replicates ± standard deviation. (L) mRNA expression levels (FPKM) for inhibitory receptors Pdcd1/PD-1,
Havcr2/TIM-3, Lag3 and Slamf6 in WT CTL ± PI3K p110d inhibitor (PI3Kdi). (D, J, K, L): *adj. P <0.05 and fold change >1.5 or <0.67.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 69199712
Spinelli et al. PI3Kp110d Transcriptome in T Cellsincreases mRNA expression of the important inhibitory receptor
Ctla4 (Figure 4J). Increased Ctla4 expression was also seen in
TCR activated CTL treated with the PI3K p110d inhibitor for 4 h
(Figure 4K). In this respect other critical inhibitory receptors
that control CTL function are PD-1, LAG3, TIM3 and SLAMF6:
there is no effect of PI3K p110d inhibition on the mRNA
expression of PD-1 or TIM3 but the mRNA expression of
LAG3 and SLAMF6 is induced by loss of PI3K p110d activity
(Figure 4L). These results inform that the activation of PI3K
p110d represses the expression of three important inhibitory
receptors: Ctla4, Slamf6 and Lag3 in CTL.
The Contribution of PKB/AKT, FOXO1 and
ERK1/2 to the Control of Cytokine and
Chemokine Production in CTL
One major role for PI3K p110d in CTL is to control the nuclear
localisation of the transcription factor FOXO1. CTL have high levels
of PtdIns(3,4,5)P3 which drives phosphorylation and activation of
the serine/threonine kinase AKT which phosphorylates FOXO1
causing its nuclear exclusion. Inhibition of PI3K p110d, which
prevents PtdIns(3,4,5)P3 production and AKT phosphorylation,
causes a rapid translocation of FOXO1 to the nucleus [Figure 5A
and (6)]. Here, a pertinent point is that the PI3K p110d repression
of CD62L, CCR7, S1P1R, IL7R, TCF7 and KLF2 is mediated by
FOXO1 (29, 49). A key question then is whether the repressive effect
that PI3K p110d activity has on the expression of Ctla4, Slamf6 and
Lag3 mRNA in CTL is mediated by FOXO1. In this context, it has
been described that the expression of PD-1 in CD8+ T cells is
FOXO1 mediated (28) but the role of FOXO1 in controlling
expression of other inhibitory receptors in CTL has not
been examined.
To explore the mechanisms used by PI3K p110d to control T cells
we analysed the impact of PI3K p110d inhibition on the expression of
mRNA encoding CTLA4, SLAMF6, PD-1, TIM-3 and LAG3 in
FOXO1 null CTL (FOXO1-GFP KO). To delete Foxo1 in CTL we
backcrossed mice with floxed Foxo1-EGFP alleles (32) to transgenic
mice expressing Cre recombinase under the control of a granzyme B
promoter that allows deletion of FOXO1-GFP in CTL (Figure 5B,
Supplementary Figures 5A, B). In normal CTL >90% of FOXO1 is
excluded from the nucleus and hence is transcriptionally inactive,
whereas in CTL treated with the PI3K p110d inhibitor FOXO1
relocates to the nucleus. We therefore performed RNA sequencing of
FOXO1-GFP null CTL before and after 24 h treatment with the PI3K
p110d inhibitor and compared to WT treated CTL (Supplementary
Datasheet 3). The full list of FOXO1 dependent mRNA identified in
these experiments is shown in supplemental data (Supplementary
Table 6) and includes previously identified FOXO1 targets including
Tcf7, Klf2 and S1pr1 and as well as the transcription factor Hif1a
(Figure 5C). There were also mRNAs whose expression was
enhanced in FOXO1 null CTL (Figure 5C). These data also show
that the expression of Ctla4 and Slamf6 mRNA is dependent on
FOXO1 (Figure 5D). In this respect, recent chromatin analysis
(ChIP-seq) has identified FOXO1 binding to Ctla4 and Slamf6
gene loci and ATAC-seq analytic comparisons of wild type and
FOXO1 null CD8+ T cells have indicated reduced chromatin
accessibility in the Ctla4 and Slamf6 gene loci in FOXO1 null
CD8+ T cells [Supplementary Figure 6A and (50)].Frontiers in Immunology | www.frontiersin.org 13Interestingly, not all inhibitory receptor mRNA expression was
changed in FOXO1 null CTL. Figure 5D shows Lag3mRNA is still
expressed in FOXO1 null CTL, though it is marginally lower, and
PD-1 and TIM-3 are not regulated by PI3K p110d or FOXO1
(Figure 5D). It is also pertinent that not all the PI3K p110d
regulated mRNA in CTL are sensitive to FOXO1 deletion
(Figure 6A; Supplementary Table 7 and Supplementary
Datasheet 3). For example, inhibition of PI3K p110d in CTL
causes decreased expression of chemokine (Ccl3, Ccl4) and
cytokine (Ifng) mRNA in both WT and FOXO1 null T cells
(Figure 6B). In this respect, previous studies have shown that the
nuclear exclusion of FOXOs is necessary for the production of
Interferon gamma (23), which would be consistent with a repressive
role for FOXO1 in the control of Interferon gamma production. The
current data found no evidence for enhanced expression of
Interferon gamma mRNA in FOXO1 null CTL (Figure 6B),
which highlights that the regulation of this key cytokine is not
controlled by a simple FOXO1 dependent switch but requires co-
ordination with other signalling pathways. It also argues that the
profound effect of PI3K p110d on Interferon gamma production is
not mediated solely by PI3K p110d control of FOXOs. In this
respect, CTL lacking PI3K p110d activity show reduced activation of
the MAP kinases ERK1 and ERK2 in response to antigen receptor
engagement [Figure 6C, Supplementary Figure 7A and (29, 30)].
This is germane because the activity of ERK1/2 is necessary for
cytokine and chemokine production by antigen activated naïve
CD8+ T cells (51).We therefore evaluated the PKB/AKT and ERK1/
2 signalling requirements of antigen receptor induced cytokine and
chemokine production in CTL. The data show that TCR induced
production of multiple chemokines and cytokines is dependent on
both the activation of the PKB/AKT serine threonine kinases and
ERK1/2 activity (Figures 6D, E). In particular the PI3K p110d
controlled cytokines and chemokines mRNA, shown in Figures 3G,
H and protein in Figure 3I, are also ERK1/2 controlled
(Figures 6F–I, Supplementary Figure 8A, Supplementary
Tables 8, 9 and Supplementary Datasheets 2, 4). These data
collectively highlight that PI3K p110d control of the CD8+ T cell
transcriptional programs reflects the role of this lipid kinase in co-
ordinating the activity of multiple signalling pathways.DISCUSSION
The aim of the present study was to gain an in-depth knowledge of
the contribution of PI3K p110d to antigen receptor controlled
programs in naïve and effector CD8+ T cells to understand how this
lipid kinase controls CD8+ T cell differentiation. One important
conclusion is that the dominant targets for PI3K p110d regulation
are the secreted molecules and cell surface receptors that mediate
CD8+ T cells communication with other immune cells. The
production of multiple cytokines by TCR activated CD8+ T cells
thus requires PI3K p110d activity. Notable amongst these are
cytokines that control the activation of monocytes and
macrophages such as GM-CSF/CSF2, TNF and IFNg. One other
important insight is that PI3K p110d controls the production of
chemokines mRNAwhich orchestrate the ability of CD8+ T cells to
recruit innate immune cells to sites of infection (45, 52).June 2021 | Volume 12 | Article 691997
Spinelli et al. PI3Kp110d Transcriptome in T CellsPI3K p110d activity also selectively shapes the repertoire of
costimulatory receptor that control CD8+ T cell differentiation. For
example, in naïve CD8+ T cells, TCR induced upregulation of the
mRNA encoding the costimulatory receptor 4-1BB, which is
essential for the persistence of tissue resident CD8+ effector/
memory T cells (53–55), is dependent on PI3K p110d activity.
Further support for the concept that PI3K p110d controls the ability
of CD8+ T cells to communicate with other immune cells includes
the role of PI3K p110d in controlling expression of the inhibitory
receptors Ctla4 and Slamf6 mRNA in effector CTL. Hence the lossFrontiers in Immunology | www.frontiersin.org 14of PI3K p110d activity and the relocalisation of the transcription
factor FOXO1 to the nucleus upregulates Ctla4 and Slamf6 mRNA
expression. The significance of this result stems from the essential
role that CTLA4 and SLAMF6 have as immunomodulatory/
inhibitory receptors that restrain peripheral T cell responses to
maintain peripheral tolerance (56–58). In this context, an elegant
study by Kaech and colleagues has shown that FOXO1 is necessary
for the differentiation of PD-1hi Eomeshi terminally exhausted CTL.
Moreover, FOXO1 null cytotoxic T cells fail to persist and control
chronic viral infection (28). The authors hypothesised that theA B
D
C
FIGURE 5 | Ctla4 and Slamf6 mRNA are modulated by FOXO1 in CTL. FOXO1-GFP null and WT CTL maintained for 24 h in the presence or absence of the PI3K
p110d inhibitor IC87114 (PI3Kdi) were subjected to RNAseq and their transcriptomes compared. (A) Nuclear localisation of FOXO1-GFP analysed by flow cytometry
in IL-2 maintained CTL and after 1 h treatment with the PI3K p110d inhibitor. Left panel: purified nuclei from WT CTL (expressing untagged FOXO1) and FOXO1-GFP
CTL were compared. The green line indicates detection of FOXO1-GFP expression level in the nucleus (top) or total cell (bottom). Right panel: purified nuclei (top) or
total cells (bottom) from FOXO1-GFP CTL either maintained in IL-2 (grey filled line) or treated with PI3K p110d inhibitor for 1 h (red line) were compared. The right
shift of the red line compared to the grey filled line indicates an increased level of FOXO1-GFP in the nuclei of PI3K p110d inhibitor treated cells (top right), while there
is no change in the total FOXO1 protein level (bottom right). Graph of treated cells is representative of three biological replicates. (B) Representative histogram
showing the deletion of FOXO1-GFP quantified by flow cytometry in CTL generated from FOXO1-GFPfl/flGzmB cre+ (grey dashed line FOXO1-GFP KO) versus
FOXO1-GFPfl/flGzmB cre− (green solid line FOXO1-GFP) mice. (C) mRNA expression levels (FPKM) of Tcf7, Klf7, S1pr1 and Hif1a in WT and FOXO1-GFP KO CTL
lacking PI3K p110d activity. (D) Histograms showing mRNA expression levels (FPKM) for inhibitory receptors Ctla4, Slamf6, Lag3, Pdcd4/PD-1 and Havcr2/TIM3 in
WT and FOXO1-GFP KO CTL ± PI3K p110d inhibitor (PI3Kdi). (C, D) FPKM shown as the mean of three biological replicates ± standard deviation. *adj. P <0.05 and
fold change >1.5 or <0.67.June 2021 | Volume 12 | Article 691997






FIGURE 6 | Contribution of PKB/AKT, FOXO1 and ERK1/2 to the control of cytokine and chemokine production in CTL. (A) Venn diagram showing the overlap in
the number of mRNA whose expression was induced by sustained PI3K p110d inhibition in WT CTL and reduced in treated FOXO1-GFP KO CTL versus WT treated
CTL. (B) mRNA expression levels (FPKM) of Ccl4, Ccl3 and Ifng in WT and FOXO1-GFP KO CTL ± PI3K p110d inhibitor. *adj. P <0.05 and fold change >1.5 or
<0.67. (C) Quantification of phosphorylated AKT (S473 and T308) and ERK1/2 (T202/Y204) in CTL in response to TCR stimulation in the presence or absence of
PI3K p110d (PI3Kdi) or MEK (MEKi) inhibitor assayed by western blot (Supplementary Figure 7A). (D) Levels of Interferon gamma (IFNg) and Tumour necrosis
factor alpha (TNFa) present in the supernatant of P14 CTL unstimulated and TCR retriggered in the presence or absence of either PI3K p110d (PI3Kdi), MEK (MEKi)
or AKT (AKTi) inhibitor determined by ELISA. (E) Levels of XCL1, CCL1, IL-3 and IL-2 protein secreted in the supernatant of unstimulated, TCR stimulated and TCR
stimulated CTL in the presence of either PI3K p110d (PI3Kdi), MEK (MEKi) or AKT (AKTi) inhibitor assayed by mass spectrometry. Transcriptome and proteome of
P14 CTL unstimulated and TCR retriggered in the presence or absence of either PI3K p110d (PI3Kdi) or MEK (MEKi) inhibitor were characterised by RNAseq and
mass spectrometry respectively. Impact of PI3K p110d and ERK1/2 inhibition on TCR induced cytokines and chemokines mRNA and protein expression was
assessed. (F, G) Heatmaps showing mRNA encoding for annotated (F) cytokines, growth factors and (G) chemokines (Cytokine activity GO:0005125 and
Chemokine activity GO:0008009). (H) Heatmap of proteins annotated as cytokines, growth factors and chemokines. Heatmaps show the relative mRNA abundance
or the relative protein abundance graded from low (blue) to high (red) per row. Input data for heatmaps are listed in Supplementary Datasheets 2 (F, G) and 4 (H).
(I) Overlap in the number of cytokine, growth factor and chemokine mRNA regulated by both PI3K p110d and ERK1/2. Data in (C–E) shown as the mean of three
biological replicates ± standard deviation and statistical analysis is calculated by unpaired, unequal variance t-test with Welch’s correction. The P values are
considered as follow: *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 'ns' not statistically significant.Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 69199715
Spinelli et al. PI3Kp110d Transcriptome in T Cellsimportance of FOXO1 in controlling T cell exhaustion reflected that
FOXO1 controlled expression of the inhibitory receptor PD-1 (28).
The current study forces a revision of this conclusion by
demonstrating that FOXO1 does not directly control PD-1
expression in CD8+ T cells. Hence inhibition of PI3K p110d,
which immediately causes FOXO1 to relocalise to the nucleus to
transcriptionally reprogram CTL, does not impact PD-1 expression.
Moreover, there is no loss of PD-1 expression in FOXO1 null CD8+
T cells. The expression of inhibitory receptors is thus not a simple
on/off FOXO1 switch but requires integration of multiple signals
with evidence that the oxygen environment is particularly
important (59). In terms of T cell exhaustion and the ability of
PI3K p110d to control CD8+ effector/memory T cells transition
then FOXO1 control of Ctla4 and Slamf6mRNA could be relevant
as these two molecules control T cell exhaustion (26, 60, 61).
However, the role of FOXO1 in enforcing T cell quiescence by
controlling expression of Tcf7, Klf2 and AP-1 family transcription
factors will also be important in regulating the effector/memory
versus senescent fate of CD8+ T cells (50). Moreover, PI3K p110d
and FOXO1 control of T cell trafficking, by regulating the
expression of key adhesion receptors and chemokine receptors,
will also influence CD8+ T cell immune responses in vivo as
will PI3K p110d control of the production of inflammatory
cytokines and chemokines that recruit and/or regulate innate
immune cells.
One salient insight from the current work is the magnitude and
selectivity of the effects of PI3K p110d on the transcriptional
restructuring that accompanies T cell differentiation. Hence only
6% of the TCR regulated transcripts in naïve T cells were sensitive
to loss of PI3K p110d activity and in CTL this dropped to 3%.
One notable result was that expression of the major regulatory
components of the metabolic programs that control T cell growth
and differentiation are not dependent on PI3K p110d activation. In
this respect, T cell metabolic programs are controlled by the
transcription factor Myc and serine/threonine kinase mTORC1
(mammalian target of rapamycin complex 1) (41, 48). We have
shown previously that PI3K p110d activation is not required for
mTORC1 activity in CD8+ T cells (29, 43) and the present data
found no role for PI3K p110d in Myc mRNA expression or in
controlling expression ofMyc targets. Nor did PI3K p110d prevent
expression of Hif1a mRNA in CD8+ T cells. In this respect,
analysis of the impact of mTORC1 inhibition of CTL
transcriptome identified mRNA encoding glycolytic regulators
and molecules that control lipid metabolism and ribosome
biogenesis as major targets for mTORC1 signalling pathways (7)
whereas the data herein show these were not regulated directly by
PI3K p110d. It should be emphasised there are some common
targets for mTORC1 and PI3K p110d notably KLF2 and receptors
such as CD62L and S1PR1 that control T cell trafficking (7, 29, 43).
The existence of these shared targets has historically been
explained using a linear model whereby PI3K p110d controls T
cell responses via mTORC1 (29). However, it is now recognised
that a shared requirement for PI3K p110d and mTORC1 activity
rather reflects that these signalling molecules control pathways
that can converge on a single target (43). Indeed, one key
observation herein is that even the role of PI3K p110d in
controlling T cell transcriptomes cannot be ascribed to a simpleFrontiers in Immunology | www.frontiersin.org 16linear signalling pathway. For example, the ability of PI3K p110d
to control the nuclear exclusion of FOXO1 is critical for T cell
differentiation yet PI3K p110d and PKB/AKT dependent but
FOXO1 independent mechanisms are also relevant. As well the
ability of PI3K p110d to repress the activity of ERKs can also
contribute to its ability to modulate T cell differentiation.
Finally, a fundamental finding from the present study was that
there are differences in how PI3K p110d inactivation impacts T cell
antigen receptor activated lymphocytes as they exit quiescence
versus effects in effector T cells. Effector CTL are thus far less
sensitive to loss of PI3K p110d activity than naïve T cells.
Moreover, inhibition of PI3K p110d could affect the expression
of cytolytic effector molecules such as the granzymes and perforin
in TCR activated naïve CD8+ T cells but not in CTL. PI3K p110d
inhibition could also selectively suppress the production of
cytokines and chemokines in both naïve T cells and CTL but did
not prevent degranulation and release of cytolytic molecules by
CTL. These results are pertinent because when thinking of how to
use PI3K p110d inhibitors therapeutically it is important to
consider whether the objective is to supress the effector immune
response or to prevent de novo immune activation. Many screens
focus on how inhibitors prevent primary activation of quiescent
peripheral blood derived T cells. The current study highlights how
unbiased screening of both naïve and effector populations would
give a better perspective on the potential therapeutic benefit of
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